Canopy Growth Stock Rises Amid Marijuana Rescheduling News
Canopy Growth's stock has risen recently due to the U.S. government rescheduling medical marijuana from Schedule I to Schedule III. Despite this positive development, the company's financial performance remains weak, with significant losses and a market cap that has declined by 95% over five years. The stock has gained over 30% in the past month but is still up only 2% for the year.
Tickers: $CGC
Topics: Canopy_Growth industry_reform marijuana_rescheduling stock_performance